Bixia Tang
8PUBLICATIONS
12CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (8)
Sort by Publication Date:
|Feb 06, 2025
Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insights.Xuan Wang, Hui Tian, Zhihong Chi
|Oct 17, 2024
Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma.Bixia Tang, Jun Xiao, Zhihong Chi
|Oct 04, 2024
Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial.Bixia Tang, Yu Chen, Yu Jiang
|Aug 20, 2024
Predominance of hyperprogression in mucosal melanoma during anti-PD-1 monotherapy treatment.Li Zhou, Min Cao, Haibin Zhu
|Mar 28, 2024
Five-Year Follow-Up of POLARIS-01 Phase II Trial: Toripalimab as Salvage Monotherapy in Chinese Patients With Advanced Melanoma.Bixia Tang, Rong Duan, Xiaoshi Zhang
|Jan 02, 2023
Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapy.Jie Dai, Xue Bai, Xuan Gao
Pageof 2
